Alzinova AB (SE:ALZ)
:ALZ
Top Page
Alzinova AB
(ALZ)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.57
▼(-30.73% Downside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by weak operating performance (near-zero revenue, ongoing losses) and continued cash burn, despite a low-leverage balance sheet. Technicals also weigh on the score as the stock trades below major moving averages with negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Balance sheet strength
Very low debt and minimal leverage provide durable financial flexibility for a pre-commercial biotech. This reduces insolvency risk, gives time to progress clinical programs or negotiate deals, and supports funding runway via equity or strategic partnerships over months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow creates a structural funding need. Over months this necessitates external financing or partner funding, increasing dilution risk and potentially forcing suboptimal deal terms or development delays if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low debt and minimal leverage provide durable financial flexibility for a pre-commercial biotech. This reduces insolvency risk, gives time to progress clinical programs or negotiate deals, and supports funding runway via equity or strategic partnerships over months.
Read all positive factors
Alzinova AB (ALZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr92.64M
Dividend YieldN/A
Average Volume (3M)655.64K
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue Growth-67.00%
EPS Growth13.62%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding154,398,900
10 Day Avg. Volume664,473
30 Day Avg. Volume655,642
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Alzinova AB Business Overview & Revenue Model
Company Description
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease...
How the Company Makes Money
Alzinova’s primary way of making money is through financing and partnering around its drug development programs rather than selling marketed products. The company can generate future revenue by (1) out-licensing or co-developing its Alzheimer’s ca...
Alzinova AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 30.00K | 270.00K | 16.63M | 17.32M |
| Gross Profit | 26.55M | 16.81M | 19.87M | 33.27M | 34.64M |
| EBITDA | -25.85M | -20.32M | 42.00K | -13.07M | -7.52M |
| Net Income | -26.27M | -20.55M | -16.48M | -13.07M | -7.58M |
Balance Sheet | |||||
| Total Assets | 143.43M | 133.23M | 123.19M | 111.62M | 91.69M |
| Cash, Cash Equivalents and Short-Term Investments | 319.00K | 15.50M | 22.03M | 32.04M | 28.84M |
| Total Debt | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Total Liabilities | 21.47M | 9.40M | 9.33M | 6.09M | 3.22M |
| Stockholders Equity | 121.96M | 123.82M | 113.86M | 105.53M | 88.47M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -37.05M | -34.82M | -26.95M | -27.14M |
| Operating Cash Flow | -13.03M | -20.27M | -15.21M | -10.31M | -9.82M |
| Investing Cash Flow | -26.55M | -16.78M | -19.60M | -16.63M | -17.32M |
| Financing Cash Flow | 24.41M | 30.52M | 24.80M | 30.15M | 0.00 |
Alzinova AB Technical Analysis
Negative
0.82
Price Trends
0.68
Negative
0.98
Negative
1.23
Negative
Market Momentum
-0.03
Negative
43.66
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZ, the sentiment is Negative. The current price of 0.82 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.68, and below the 200-day MA of 1.23, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 43.66 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZ.
Alzinova AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr101.08M | -1.81 | -72.82% | ― | 40.91% | 57.92% | |
44 Neutral | kr135.23M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr92.64M | -3.17 | -21.31% | ― | -67.00% | 13.62% | |
43 Neutral | kr36.61M | -1.03 | -457.91% | ― | ― | -19.35% | |
42 Neutral | kr82.19M | -1.86 | -120.13% | ― | ― | 49.09% | |
42 Neutral | kr122.96M | -1.34 | -294.38% | ― | 186.74% | 73.17% |
* Healthcare Sector Average
SE:ALZ
Alzinova AB
0.60
-1.25
-67.57%
SE:BIOSGN
Biosergen AB
35.00
1.80
5.42%
SE:NICA
Nanologica AB
0.37
-0.49
-56.61%
SE:BIOVIC.B
Biovica International AB Class B
0.35
-0.48
-57.93%
SE:MODTX
Modus Therapeutics Holding AB
0.30
-0.15
-33.85%
SE:NXTCL
NextCell Pharma AB
1.21
-1.94
-61.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.